Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
Table 2
Bone markers in patients treated with Dmab (BP-naïve and BP-prior) and BP treated patients not switched to Dmab (control group).
Basal
12 m
Change (%)
BP-naïve
tAP (IU/L)
160.60 ± 16.32
113.50 ± 11.28#
↓29.33
BGP (ng/mL)
26.78 ± 3.15&
20.22 ± 3.11#
↓24.50
s-CTX (ng/L)
509.80 ± 54.66&
101.40 ± 30.55#
↓80.11
BP-prior
tAP (IU/L)
146.00 ± 010.21
117.90 ± 8.32
↓19.25
BGP (ng/mL)
19.58 ± 1.06
10.53 ± 0.65
↓46.22
s-CTX (ng/L)
314.90 ± 17.47
101.20 ± 9.00
↓67.86
Control group
tAP (IU/L)
147.90 ± 7.01
141.30 ± 6.63
ns
BGP (ng/mL)
17.37 ± 2.00
16.08 ± 1.28
ns
s-CTX (ng/L)
275.60 ± 28.67
204.00 ± 17.05θ
↓25.98%
Significant differences with BP-naïve basal; significant differences with BP-prior basal; significant differences with BP-prior basal; θsignificant differences with control group basal.
